About Sexual Dysfunction Drugs
Sexual dysfunctions include sexual disorders of men and women that can interfere with their sexual performance, leading to unsatisfied sexual intercourse. The major drugs used in this market are PDE5 inhibitors, whereas other drugs such as hormone-related and transurethral also have a presence in the market. Erectile dysfunction (ED) is a highly prevalent sexual dysfunction seen in men. Globally, there has been an increase in the number of ED cases caused due to high blood pressure, obesity, neurological and nerve disorders, prostate cancer, and diabetes among others.
Technavio’s analysts forecast the global sexual dysfunction drugs market to grow at a CAGR of 2.79% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global sexual dysfunction drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Sexual Dysfunction Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AbbVie
• Bayer
• Eli Lilly
• Pfizer
Other prominent vendors
• Apricus Biosciences
• Emotional Brain
• GlaxoSmithKline
• Ivix LLX
• Leadiant Biosciences
• Merck
• NexMed
• Palatin Technologies and PRA Health Sciences
• S1 Biopharma
• Takeda
• Teva Pharmaceutical Industries
• Trimel Biopharma SRL
• Vietstar Biomedical Research
Market driver
• Rising prevalence of sexual dysfunctions
• For a full, detailed list, view our report
Market challenge
• Technological advancements, a threat to drug therapy
• For a full, detailed list, view our report
Market trend
• Increased focus on generic drugs
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
PART 05: Disease overview
• Sexual dysfunction: Definition
• Causes of sexual dysfunction
PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 07: Pipeline
PART 08: Market segmentation by therapy
• Oral therapy
• Intracavernosal therapy
• Hormonal therapy
• Transurethral therapy
PART 09: Geographical segmentation
• Sexual dysfunction drugs market in Americas
• Sexual dysfunction drugs market in EMEA
• Sexual dysfunction drugs market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Market challenges
PART 12: Market trends
• Increased focus on generic drugs
• Migration of manufacturing and sales facilities to APAC
• Advancing biomedical science
PART 13: Vendor landscape
• Competitive scenario
PART 14: Key vendor analysis
• AbbVie
• Bayer
• Eli Lilly
• Pfizer
• Other prominent members
PART 15: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Symptoms of sexual dysfunction in men and women
Exhibit 02: Types of sexual disorder
Exhibit 03: Causes of sexual dysfunction
Exhibit 04: Regional prevalence rate of ED June 2016
Exhibit 05: Global sexual dysfunction drugs market: Snapshot
Exhibit 06: Global sexual dysfunction drugs market 2016-2021 ($ millions)
Exhibit 07: Key drugs patent expiration in major countries
Exhibit 08: Opportunity analysis of global sexual dysfunction drugs market
Exhibit 09: Five forces analysis
Exhibit 10: Pipeline snapshot based on number of molecules 2016
Exhibit 11: Pipeline snapshot based on types of sexual dysfunction 2016
Exhibit 12: Key clinical trials
Exhibit 13: Global sexual dysfunction drugs market segmentation by therapy 2016
Exhibit 14: Oral therapies used as per drug class
Exhibit 15: Global sexual dysfunction oral drugs market 2016-2021 ($ millions)
Exhibit 16: Intracavernosal therapy used as per drug class
Exhibit 17: Global sexual dysfunction intracavernosal drugs market 2016-2021 ($ millions)
Exhibit 18: Some marketed intracavernosal drugs
Exhibit 19: Hormonal therapy used as per drug class
Exhibit 20: Global sexual dysfunction hormonal drugs market 2016-2021 ($ millions)
Exhibit 21: Transurethral therapy used as per drug class
Exhibit 22: Global sexual dysfunction transurethral drugs market 2016-2021 ($ millions)
Exhibit 23: Global sexual dysfunction drugs market share by geography 2016 and 2021
Exhibit 24: Global sexual dysfunction drugs market revenue by geography 2016-2021
Exhibit 25: Global sexual dysfunction drugs market share by geography 2016-2021
Exhibit 26: Snapshot of Global sexual dysfunction drugs market by geography 2016 and 2021
Exhibit 27: Market scenario in Americas
Exhibit 28: Sexual dysfunction drugs market in Americas 2016-2021 ($ millions)
Exhibit 29: Market scenario in EMEA
Exhibit 30: Sexual dysfunction drugs market in EMEA 2016-2021 ($ millions)
Exhibit 31: Market scenario in APAC
Exhibit 32: Sexual dysfunction drugs market in APAC 2016-2021 ($ millions)
Exhibit 33: Prevalence data of sexual dysfunction in women and men every year
Exhibit 34: Geriatric population analysis and estimates 2000 and 2030 (millions)
Exhibit 35: Mean number of prostate cancer diagnoses by five-year age band 2008-2010
Exhibit 36: Prevalence of ED in stroke patients 2008
Exhibit 37: Competitive structure analysis of global sexual dysfunction drugs market 2016
Exhibit 38: AbbVie: Key highlights
Exhibit 39: AbbVie: Strength assessment
Exhibit 40: AbbVie: Strategy assessment
Exhibit 41: AbbVie: Opportunity assessment
Exhibit 42: Bayer: Key highlights
Exhibit 43: Bayer: Strength assessment
Exhibit 44: Bayer: Strategy assessment
Exhibit 45: Bayer: Opportunity assessment
Exhibit 46: Eli Lilly: Key highlights
Exhibit 47: Eli Lilly: Strength assessment
Exhibit 48: Eli Lilly: Strategy assessment
Exhibit 49: Eli Lilly: Opportunity assessment
Exhibit 50: Pfizer: Key highlights
Exhibit 51: Pfizer: Strength assessment
Exhibit 52: Pfizer: Strategy assessment
Exhibit 53: Pfizer: Opportunity assessment
